Non Alcoholic Fatty Liver Disease Treatment Market - Global Outlook and Forecast 2021-2027

Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Non Alcoholic Fatty Liver Disease Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non Alcoholic Fatty Liver Disease Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non Alcoholic Fatty Liver Disease Treatment Overall Market Size
2.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Size: 2021 VS 2027
2.2 Global Non Alcoholic Fatty Liver Disease Treatment Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non Alcoholic Fatty Liver Disease Treatment Players in Global Market
3.2 Top Global Non Alcoholic Fatty Liver Disease Treatment Companies Ranked by Revenue
3.3 Global Non Alcoholic Fatty Liver Disease Treatment Revenue by Companies
3.4 Top 3 and Top 5 Non Alcoholic Fatty Liver Disease Treatment Companies in Global Market, by Revenue in 2020
3.5 Global Companies Non Alcoholic Fatty Liver Disease Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non Alcoholic Fatty Liver Disease Treatment Players in Global Market
3.6.1 List of Global Tier 1 Non Alcoholic Fatty Liver Disease Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Non Alcoholic Fatty Liver Disease Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non Alcoholic Fatty Liver Disease Treatment Market Size Markets, 2021 & 2027
4.1.2 Antioxidants
4.1.3 Thiazolidinedione
4.1.4 Biguanides
4.1.5 Lipid lowering Agents
4.1.6 FXR Receptor Agonist
4.1.7 Others
4.2 By Type - Global Non Alcoholic Fatty Liver Disease Treatment Revenue & Forecasts
4.2.1 By Type - Global Non Alcoholic Fatty Liver Disease Treatment Revenue, 2016-2021
4.2.2 By Type - Global Non Alcoholic Fatty Liver Disease Treatment Revenue, 2022-2027
4.2.3 By Type - Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non Alcoholic Fatty Liver Disease Treatment Market Size, 2021 & 2027
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.1.4 Drug Stores
5.1.5 Online Pharmacy
5.1.6 Others
5.2 By Application - Global Non Alcoholic Fatty Liver Disease Treatment Revenue & Forecasts
5.2.1 By Application - Global Non Alcoholic Fatty Liver Disease Treatment Revenue, 2016-2021
5.2.2 By Application - Global Non Alcoholic Fatty Liver Disease Treatment Revenue, 2022-2027
5.2.3 By Application - Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share, 2016-2027
6 Sights by Region
6.1 By Region - Global Non Alcoholic Fatty Liver Disease Treatment Market Size, 2021 & 2027
6.2 By Region - Global Non Alcoholic Fatty Liver Disease Treatment Revenue & Forecasts
6.2.1 By Region - Global Non Alcoholic Fatty Liver Disease Treatment Revenue, 2016-2021
6.2.2 By Region - Global Non Alcoholic Fatty Liver Disease Treatment Revenue, 2022-2027
6.2.3 By Region - Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share, 2016-2027
6.3 North America
6.3.1 By Country - North America Non Alcoholic Fatty Liver Disease Treatment Revenue, 2016-2027
6.3.2 US Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.3.3 Canada Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.3.4 Mexico Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.4 Europe
6.4.1 By Country - Europe Non Alcoholic Fatty Liver Disease Treatment Revenue, 2016-2027
6.4.2 Germany Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.4.3 France Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.4.4 U.K. Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.4.5 Italy Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.4.6 Russia Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.4.7 Nordic Countries Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.4.8 Benelux Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.5 Asia
6.5.1 By Region - Asia Non Alcoholic Fatty Liver Disease Treatment Revenue, 2016-2027
6.5.2 China Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.5.3 Japan Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.5.4 South Korea Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.5.5 Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.5.6 India Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.6 South America
6.6.1 By Country - South America Non Alcoholic Fatty Liver Disease Treatment Revenue, 2016-2027
6.6.2 Brazil Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.6.3 Argentina Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Revenue, 2016-2027
6.7.2 Turkey Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.7.3 Israel Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.7.4 Saudi Arabia Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
6.7.5 UAE Non Alcoholic Fatty Liver Disease Treatment Market Size, 2016-2027
7 Players Profiles
7.1 Pfizer
7.1.1 Pfizer Corporate Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.1.4 Pfizer Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.1.5 Pfizer Key News
7.2 Roche
7.2.1 Roche Corporate Summary
7.2.2 Roche Business Overview
7.2.3 Roche Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.2.4 Roche Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.2.5 Roche Key News
7.3 Daewoong
7.3.1 Daewoong Corporate Summary
7.3.2 Daewoong Business Overview
7.3.3 Daewoong Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.3.4 Daewoong Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.3.5 Daewoong Key News
7.4 Cardax
7.4.1 Cardax Corporate Summary
7.4.2 Cardax Business Overview
7.4.3 Cardax Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.4.4 Cardax Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.4.5 Cardax Key News
7.5 Merck
7.5.1 Merck Corporate Summary
7.5.2 Merck Business Overview
7.5.3 Merck Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.5.4 Merck Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.5.5 Merck Key News
7.6 Novartis
7.6.1 Novartis Corporate Summary
7.6.2 Novartis Business Overview
7.6.3 Novartis Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.6.4 Novartis Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.6.5 Novartis Key News
7.7 Gilead Sciences
7.7.1 Gilead Sciences Corporate Summary
7.7.2 Gilead Sciences Business Overview
7.7.3 Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.4.4 Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.7.5 Gilead Sciences Key News
7.8 AstraZeneca
7.8.1 AstraZeneca Corporate Summary
7.8.2 AstraZeneca Business Overview
7.8.3 AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.8.4 AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.8.5 AstraZeneca Key News
7.9 Limerick BioPharma
7.9.1 Limerick BioPharma Corporate Summary
7.9.2 Limerick BioPharma Business Overview
7.9.3 Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.9.4 Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.9.5 Limerick BioPharma Key News
7.10 GW Pharmaceuticals
7.10.1 GW Pharmaceuticals Corporate Summary
7.10.2 GW Pharmaceuticals Business Overview
7.10.3 GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.10.4 GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.10.5 GW Pharmaceuticals Key News
7.11 Allergan
7.11.1 Allergan Corporate Summary
7.11.2 Allergan Business Overview
7.11.3 Allergan Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.11.4 Allergan Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.11.5 Allergan Key News
7.12 Takeda Pharmaceutical
7.12.1 Takeda Pharmaceutical Corporate Summary
7.12.2 Takeda Pharmaceutical Business Overview
7.12.3 Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Major Product Offerings
7.12.4 Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (2016-2021)
7.12.5 Takeda Pharmaceutical Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer


List of Tables
Table 1. Non Alcoholic Fatty Liver Disease Treatment Market Opportunities & Trends in Global Market
Table 2. Non Alcoholic Fatty Liver Disease Treatment Market Drivers in Global Market
Table 3. Non Alcoholic Fatty Liver Disease Treatment Market Restraints in Global Market
Table 4. Key Players of Non Alcoholic Fatty Liver Disease Treatment in Global Market
Table 5. Top Non Alcoholic Fatty Liver Disease Treatment Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Non Alcoholic Fatty Liver Disease Treatment Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Share by Companies, 2016-2021
Table 8. Global Companies Non Alcoholic Fatty Liver Disease Treatment Product Type
Table 9. List of Global Tier 1 Non Alcoholic Fatty Liver Disease Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non Alcoholic Fatty Liver Disease Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type - Global Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application - Global Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Non Alcoholic Fatty Liver Disease Treatment Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region - Global Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2022-2027
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 32. Pfizer Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
Table 33. Roche Corporate Summary
Table 34. Roche Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 35. Roche Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
Table 36. Daewoong Corporate Summary
Table 37. Daewoong Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 38. Daewoong Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
Table 39. Cardax Corporate Summary
Table 40. Cardax Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 41. Cardax Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
Table 42. Merck Corporate Summary
Table 43. Merck Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 44. Merck Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
Table 45. Novartis Corporate Summary
Table 46. Novartis Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 47. Novartis Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
Table 48. Gilead Sciences Corporate Summary
Table 49. Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 50. Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
Table 51. AstraZeneca Corporate Summary
Table 52. AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 53. AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
Table 54. Limerick BioPharma Corporate Summary
Table 55. Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 56. Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
Table 57. GW Pharmaceuticals Corporate Summary
Table 58. GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 59. GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
Table 60. Allergan Corporate Summary
Table 61. Allergan Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 62. Allergan Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
Table 63. Takeda Pharmaceutical Corporate Summary
Table 64. Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Product Offerings
Table 65. Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Revenue (US$, Mn), (2016-2021)
List of Figures
Figure 1. Non Alcoholic Fatty Liver Disease Treatment Segment by Type
Figure 2. Non Alcoholic Fatty Liver Disease Treatment Segment by Application
Figure 3. Global Non Alcoholic Fatty Liver Disease Treatment Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Non Alcoholic Fatty Liver Disease Treatment Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Non Alcoholic Fatty Liver Disease Treatment Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non Alcoholic Fatty Liver Disease Treatment Revenue in 2020
Figure 8. By Type - Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share, 2016-2027
Figure 9. By Application - Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share, 2016-2027
Figure 10. By Region - Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share, 2016-2027
Figure 11. By Country - North America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share, 2016-2027
Figure 12. US Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share, 2016-2027
Figure 16. Germany Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 17. France Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share, 2016-2027
Figure 24. China Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 28. India Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share, 2016-2027
Figure 30. Brazil Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share, 2016-2027
Figure 33. Turkey Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Non Alcoholic Fatty Liver Disease Treatment Revenue, (US$, Mn), 2016-2027
Figure 37. Pfizer Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Roche Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Daewoong Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Cardax Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Merck Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Novartis Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. Allergan Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 48. Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)

Pfizer
Roche
Daewoong
Cardax
Merck
Novartis
Gilead Sciences
AstraZeneca
Limerick BioPharma
GW Pharmaceuticals
Allergan
Takeda Pharmaceutical